Skip to main content
Skip to navigation
Research Exchange
Living Lab
Discovery Lab
Donate
Grant
A SIK2 Inhibitor, GRN-300, enhances Response to Paclitaxel and PARP Inhibitors and induces PD-L1 expression in Triple Negative Breast Cancer
SRA-22-193-01-SRA
Status
completed
Period
2022-11-01 — 2025-10-01
A SIK2 Inhibitor, GRN-300, enhances Response to Paclitaxel and PARP Inhibitors and induces PD-L1 expression in Triple Negative Breast Cancer
